Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RefIsh: encorafenib plus cetuximab rechallenge in BRAF V600E-mutant mCRC
2023-509564-22-00Phase 2Authorised
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of encorafenib and cetuximab in colorectal cancer (CRC), sponsored by Vall d'Hebron Institute of Oncology. Primary endpoint: Progression-free survival rate at 4 months. Planned start Jul 2025; status: authorised.
02
Drugs
encorafenibcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-509564-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509564-22-00.